-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Therapeutic Targeting of JAK/STAT Signaling and Histone Acetyltransferase Activity in Post-Myeloproliferative Neoplasm Secondary AML

Program: Special-Interest Sessions
Session: Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology
Saturday, December 7, 2024, 6:00 PM-9:00 PM

Kalay Bertulfo, MS, MA, MPhil

Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY

Disclosures: No relevant conflicts of interest to declare.